openPR Logo
Press release

Investigation announced for Investors in NASDAQ: AMRN shares over potential Violations of Securities Laws by Amarin Corporation plc

08-15-2019 10:40 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Amarin Corporation plc (NASDAQ: AMRN) shares over potential securities laws violations.

An investigation for investors in Amarin Corporation plc (NASDAQ: AMRN) shares over potential securities laws violations.

An investigation was announced concerning potential securities laws violations by Amarin Corporation plc in connection with certain financial statements.

Investors who purchased shares of Amarin Corporation plc (NASDAQ: AMRN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Amarin Corporation plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Ireland based Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. On August 8, 2019, Amarin Corporation plc announced that it received notice from the FDA that it plans to hold an advisory committee meeting, tentatively scheduled for November 14, 2019, in connection with its review of the pending supplemental new drug application for expansion of Vascepa. Amarin Corporation plc stated that the FDA's deadline for making an approval decision on Vascepa would likely be extended.
Just one week earlier, on July 31, 2019, Amarin Corporation plc said it was unlikely that the FDA would proceed with an advisory panel review regarding approval of Vascepa and anticipated a September 28, 2019 approval.

Shares of Amarin Corporation plc (NASDAQ: AMRN) declined to as low as $13.76 per share on August 12, 2019.

Those who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in NASDAQ: AMRN shares over potential Violations of Securities Laws by Amarin Corporation plc here

News-ID: 1822653 • Views: 433

More Releases from Shareholders Foundation

ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) Investor Alert: Deadline in …
A deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) over alleged securities laws violations. Investors who purchased shares of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSEArca: UCO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Forescout Technolog …
An investigation was announced for long-term investors in shares of Forescout Technologies, Inc. (NASDAQ: FSCT) concerning potential breaches of fiduciary duties by certain directors and officers of Forescout Technologies, Inc.. Investors who are current long term investors in Forescout Technologies, Inc. (NASDAQ: FSCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ:
Investigation announced for Long-Term Investors in shares of Hebron Technology C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Hebron Technology Co., Ltd.. Investors who are current long term investors in Hebron Technology Co., Ltd. (NASDAQ: HEBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: HEBT stocks follows a lawsuit filed against Hebron
Investigation announced for Investors in shares of CrossFirst Bankshares, Inc. ( …
An investigation was announced concerning potential securities laws violations by CrossFirst Bankshares, Inc. in connection with certain financial statements. Investors who purchased shares of CrossFirst Bankshares, Inc. (NASDAQ: CFB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by CrossFirst Bankshares, Inc. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Amarin

Marine Pharmaceuticals Market Share and Growth 2019| Abbott Laboratories, AbbVie …
The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Marine Pharmaceuticals market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Marine Pharmaceuticals Market. We have provided deep analysis of the vendor landscape to give you a
Global Dyslipidemia Drugs Market Overview, Applications, Pharmaceuticals Researc …
The global market status for Dyslipidemia Drugs is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Dyslipidemia Drugs Market Research Report 2019”, which tends to deliver in-depth knowledge associated to the Dyslipidemia Drugs market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market size, revenue and
Marine Pharmaceuticals Market Competitive Share & Forecast 2019| Abbott Laborato …
The report presented here is a comprehensive research study that explores key aspects of the global Marine Pharmaceuticals market, including market dynamics, segmentation, competition, and regional growth. Each section of the report reveals critical information about the global Marine Pharmaceuticals market that could be used to ensure strong growth in the coming years. All of the segments included in the report are studied on the basis of different factors such
Global Marine Pharmaceuticals Market Is Booming Worldwide | Market Segment by Ma …
The marine life is extremely diverse and the creature has evolved to produce unique defensive compounds. Marine Pharmaceuticals derived from the marine creatures and micro-organisms can be useful as anti-bacterial, anti-fungal, anti-coagulant, and anti-viral. Scientists are actively screening marine organisms for biological active substances that may have a variety of potential uses and already found several of them with potent chemicals. Marine Pharmaceuticals market Report points out the latest trends and
Hypercholesterolemia Drugs Market new Technology, Application, Type, Customer Se …
Hypercholesterolemia is a condition caused by presence of high amounts of cholesterol in the blood. It can be caused by unhealthy diet intake, obesity or because of incidence of other diseases such as diabetes and an underactive thyroid, in some cases its hereditary. The condition can be life threating if not treated, hence anti-hyperlipidemic drugs are utilized to keep the condition in check and to avoid further health complication such